Suppr超能文献

阑尾黏液性肿瘤腹膜假性黏液瘤行细胞减灭术和腹腔内热灌注化疗后肺胸膜复发。

Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.

机构信息

Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

The University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, PA, USA.

出版信息

Ann Surg Oncol. 2019 May;26(5):1429-1436. doi: 10.1245/s10434-018-07091-z. Epub 2019 Jan 8.

Abstract

BACKGROUND

The aim of this study was to identify factors associated with pleuropulmonary disease recurrence following cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) for appendiceal pseudomyxoma peritonei (PMP) and to evaluate the oncologic impact of pleuropulmonary disease recurrence compared with isolated peritoneal recurrence.

METHODS

From a prospective database, we identified patients who developed pleuropulmonary recurrence, isolated peritoneal recurrence, or no recurrence following CRS/HIPEC for appendiceal PMP. Clinicopathologic, perioperative, and oncologic data associated with the index CRS/HIPEC procedure were reviewed. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with recurrence and survival.

RESULTS

Of 382 patients undergoing CRS/HIPEC, 61 (16%) developed pleuropulmonary recurrence. Patients who developed a pleuropulmonary recurrence were more likely to have high-grade (American Joint Committee on Cancer [AJCC] grade 2/3) tumors (74% vs. 56%, p = 0.02) and increased operative blood loss (1651 vs. 1201 ml, p = 0.05) and were more likely to have undergone diaphragm stripping/resection (79% vs. 48%, p < 0.01) compared with patients with an abdominal recurrence. In a multivariate analysis, pleuropulmonary recurrence after CRS/HIPEC was associated with diaphragm stripping/resection, incomplete cytoreduction, and higher AJCC tumor grade. There was a trend towards reduced survival in patients with pleuropulmonary recurrence compared with patients with isolated peritoneal recurrence (median overall survival 45 vs. 53 months, p = 0.87).

CONCLUSION

Pleuropulmonary recurrence of appendiceal PMP following CRS/HIPEC is common and may negatively impact survival. Formal protocols for surveillance and therapeutic intervention need to be studied and implemented to improve oncologic outcomes.

摘要

背景

本研究旨在确定行细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)治疗阑尾黏液性肿瘤(PMP)后并发胸膜肺疾病复发的相关因素,并评估与单纯腹膜复发相比,胸膜肺疾病复发的肿瘤学影响。

方法

我们从前瞻性数据库中确定了在接受 CRS/HIPEC 治疗阑尾 PMP 后发生胸膜肺复发、单纯腹膜复发或无复发的患者。回顾了与指数 CRS/HIPEC 手术相关的临床病理、围手术期和肿瘤学数据。采用 Kaplan-Meier 法估计生存。多变量分析确定了与复发和生存相关的因素。

结果

在 382 例接受 CRS/HIPEC 的患者中,有 61 例(16%)发生了胸膜肺复发。发生胸膜肺复发的患者更有可能患有高级别(美国癌症联合委员会 [AJCC] 分级 2/3)肿瘤(74%比 56%,p=0.02)和更多的手术失血量(1651 比 1201 ml,p=0.05),并且更有可能接受膈肌剥离/切除术(79%比 48%,p<0.01)。在多变量分析中,CRS/HIPEC 后胸膜肺复发与膈肌剥离/切除术、不完全细胞减灭术和更高的 AJCC 肿瘤分级相关。与单纯腹膜复发的患者相比,胸膜肺复发的患者生存时间有缩短的趋势(中位总生存时间 45 比 53 个月,p=0.87)。

结论

CRS/HIPEC 治疗阑尾 PMP 后并发胸膜肺复发较为常见,可能对生存产生负面影响。需要研究和实施规范的监测和治疗干预方案,以改善肿瘤学结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验